Travere Therapeutics, Inc. (TVTX)

NGM – Цена в реальном времени. Валюта: USD

42.84

-0.67 (-1.54%)

При закрытии: May 12, 2026, 4:00 PM EDT

12.05.2026

Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

SAN DIEGO--(BUSINESS WIRE)--Travere Therapeutics, Inc. (Nasdaq: TVTX) today announced that on May 10, 2026, the Compensation Committee of its Board of Directors granted inducement equity grants covering an aggregate of 48,800 shares of its common stock to four new employees, consisting of inducement stock options to purchase an aggregate of 18,000 shares of common stock and inducement restricted stock units, or RSUs, covering an aggregate of 30,800 shares of its common stock. These inducement s.

07.05.2026

Travere Therapeutics to Participate at Upcoming Investor Conferences

SAN DIEGO--(BUSINESS WIRE)--Travere Therapeutics, Inc. (Nasdaq: TVTX) today announced that company management will participate in the following upcoming investor conferences: BofA Securities 2026 Health Care Conference Presenting on Wednesday, May 13, 2026, at 5:20 p.m. ET (2:20 p.m. PT) 2026 Jefferies Global Healthcare Conference Presenting on Wednesday, June 3, 2026, at 8:45 a.m. ET Goldman Sachs 47th Annual Global Healthcare Conference 2026 Presenting on Monday, June 8, 2026, at 11:20 a.m. E.

07.05.2026

Travere Prices Upsized $475.0 Million Convertible Senior Notes Offering to Refinance 2029 Convertible Notes

SAN DIEGO--(BUSINESS WIRE)--Travere Therapeutics, Inc. (Nasdaq: TVTX) today announced the pricing of its underwritten offering of $475.0 million aggregate principal amount of 0.50% convertible senior notes due 2032 (the “Notes”). The sale of the Notes is expected to close on May 11, 2026, subject to customary closing conditions. The aggregate principal amount of the offering was increased from the previously announced offering size of $400.0 million. Travere also granted the underwriters of the.

05.05.2026

Travere Announces Proposed Convertible Senior Notes Offering to Refinance 2029 Convertible Notes

SAN DIEGO--(BUSINESS WIRE)--Travere Therapeutics, Inc. (Nasdaq: TVTX) today announced its intention to offer, subject to market and other conditions, $400 million aggregate principal amount of convertible senior notes due 2032 (the “Notes”) in an underwritten offering. Travere also expects to grant the underwriters of the Notes a 30-day option to purchase up to an additional $60 million aggregate principal amount of Notes, solely to cover over-allotments. As described in more detail below, Trav.

05.05.2026

Travere Therapeutics Analysts Increase Their Forecasts Following Q1 Earnings

Travere Therapeutics (NASDAQ:TVTX) posted a profit for the first quarter on Monday.

05.05.2026

Travere Therapeutics, Inc. (TVTX) Q1 2026 Earnings Call Transcript

04.05.2026

Compared to Estimates, Travere (TVTX) Q1 Earnings: A Look at Key Metrics

The headline numbers for Travere (TVTX) give insight into how the company performed in the quarter ended March 2026, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.

Видео

No Data

There is no data to display

Пресс-релизы

12.05.2026

Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

07.05.2026

Travere Prices Upsized $475.0 Million Convertible Senior Notes Offering to Refinance 2029 Convertible Notes

05.05.2026

Travere Announces Proposed Convertible Senior Notes Offering to Refinance 2029 Convertible Notes

04.05.2026

Travere Therapeutics Reports First Quarter 2026 Financial Results

SAN DIEGO--(BUSINESS WIRE)--Travere Therapeutics, Inc. (Nasdaq: TVTX) today reported its first quarter 2026 financial results and provided a corporate update. “This has been a transformative start to the year for Travere, highlighted by the landmark approval of FILSPARI in FSGS, record demand that reinforces FILSPARI's foundational position in IgAN, and the advancement of pegtibatinase with the first new patient dosed in the restarted Phase 3 HARMONY study,” said Eric Dube, Ph.D., president and.

Travere Therapeutics, Inc. (TVTX)

Получите доступ ко всем премиум-функциям лучшего инструмента для анализа акций

Finranks

Компания

Контакты

Мы в соцсетях

Travere Therapeutics, Inc. (TVTX)

Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Travere Therapeutics to Participate at Upcoming Investor Conferences

Travere Prices Upsized $475.0 Million Convertible Senior Notes Offering to Refinance 2029 Convertible Notes

Travere Announces Proposed Convertible Senior Notes Offering to Refinance 2029 Convertible Notes

Travere Therapeutics Analysts Increase Their Forecasts Following Q1 Earnings

Travere Therapeutics, Inc. (TVTX) Q1 2026 Earnings Call Transcript

Compared to Estimates, Travere (TVTX) Q1 Earnings: A Look at Key Metrics

Видео

No Data

Пресс-релизы

Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Travere Prices Upsized $475.0 Million Convertible Senior Notes Offering to Refinance 2029 Convertible Notes

Travere Announces Proposed Convertible Senior Notes Offering to Refinance 2029 Convertible Notes

Travere Therapeutics Reports First Quarter 2026 Financial Results

Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Travere Therapeutics to Participate at Upcoming Investor Conferences

Travere Prices Upsized $475.0 Million Convertible Senior Notes Offering to Refinance 2029 Convertible Notes

Travere Announces Proposed Convertible Senior Notes Offering to Refinance 2029 Convertible Notes

Travere Therapeutics Analysts Increase Their Forecasts Following Q1 Earnings

Travere Therapeutics, Inc. (TVTX) Q1 2026 Earnings Call Transcript

Compared to Estimates, Travere (TVTX) Q1 Earnings: A Look at Key Metrics

Видео

No Data

Пресс-релизы

Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Travere Prices Upsized $475.0 Million Convertible Senior Notes Offering to Refinance 2029 Convertible Notes

Travere Announces Proposed Convertible Senior Notes Offering to Refinance 2029 Convertible Notes

Travere Therapeutics Reports First Quarter 2026 Financial Results

Search stocks

Travere Therapeutics, Inc. (TVTX)

Получите доступ ко всем премиум-функциям лучшего инструмента для анализа акций

Finranks

Компания

Контакты

Мы в соцсетях

Travere Therapeutics, Inc. (TVTX)

Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Travere Therapeutics to Participate at Upcoming Investor Conferences

Travere Prices Upsized $475.0 Million Convertible Senior Notes Offering to Refinance 2029 Convertible Notes

Travere Announces Proposed Convertible Senior Notes Offering to Refinance 2029 Convertible Notes

Travere Therapeutics Analysts Increase Their Forecasts Following Q1 Earnings

Travere Therapeutics, Inc. (TVTX) Q1 2026 Earnings Call Transcript

Compared to Estimates, Travere (TVTX) Q1 Earnings: A Look at Key Metrics

Видео

No Data

Пресс-релизы

Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Travere Prices Upsized $475.0 Million Convertible Senior Notes Offering to Refinance 2029 Convertible Notes

Travere Announces Proposed Convertible Senior Notes Offering to Refinance 2029 Convertible Notes

Travere Therapeutics Reports First Quarter 2026 Financial Results

Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Travere Therapeutics to Participate at Upcoming Investor Conferences

Travere Prices Upsized $475.0 Million Convertible Senior Notes Offering to Refinance 2029 Convertible Notes

Travere Announces Proposed Convertible Senior Notes Offering to Refinance 2029 Convertible Notes

Travere Therapeutics Analysts Increase Their Forecasts Following Q1 Earnings

Travere Therapeutics, Inc. (TVTX) Q1 2026 Earnings Call Transcript

Compared to Estimates, Travere (TVTX) Q1 Earnings: A Look at Key Metrics

Видео

No Data

Пресс-релизы

Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Travere Prices Upsized $475.0 Million Convertible Senior Notes Offering to Refinance 2029 Convertible Notes

Travere Announces Proposed Convertible Senior Notes Offering to Refinance 2029 Convertible Notes

Travere Therapeutics Reports First Quarter 2026 Financial Results